Blood Pressure LIMBO How Low To Go?
|
|
- Damian Heath
- 5 years ago
- Views:
Transcription
1 Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity and mortality, much mediated through cardiovascular disease Optimal BP goals are controversial. Need to balance benefits vs side effects, costs, and convenience of therapeutic interventions Hypertension Epidemiology Over 60 million Americans have hypertension, a prevalence of about 3 of 10 adults About half of the US adult population older than 65 are hypertensive Of these, 70% are aware of their disease, 59% are receiving treatment, and only 34% are adequately treated 1
2 Hypertension Epidemiology Treating hypertension has been shown to: Reduce Stroke by 35-40% Reduce Myocardial Infarction by 15-25% Reduce Heart Failure by up to 64% JNC-7 Guidelines (2003) Goal BP for an otherwise healthy adult 140/90 mmhg With Diabetes or Renal Insufficiency 130/80 mmhg Without a compelling indication, start medical therapy with a diuretic. Strongly consider initial therapy with two medications. JNC VII Lifestyle Modifications for BP Control Modification Recommendation SBP Reduction Weight Reduction Keep BMI kg/m mmhg per 10kg Weight Loss DASHEating Plan Fruits, vegetables, low-fat dairy;reduced saturated and total fat 8-14 mmhg DietarySodium Restriction 2.4 gm Na + (6 gm NaCl)daily 2-8 mmhg Physical Activity At least 30 minutes aerobic 4-9 mmhg activity most days of the week Moderate EtOHConsumption Up to 2 drinks/day for men, 1 for women 2-4 mmhg ChobanianAV et al. JAMA. 2003;289:
3 ACCORD Trial ACCORD-BP 1 Excellent trial design year olds with Type II DM 4377 Subjects, 5 Year follow-up (Released 2010) Known CAD (pre-existing or subclinical) or at least two additional CAD risk factors 1 The ACCORD Study Group. NEJM 2010; 362: ACCORD Trial ACCORD-BP Compared SBP goal < 120 mmhg to < 140 mmhg in these high risk diabetics Several medication combinations used Primary end point Non-fatal MI, Non-fatal CVA, Cardiovascular Death ACCORD Trial NO difference in major cardiac outcomes 40% lower absolute risk of non-fatal stroke Higher risk of adverse events in the intensive treatment group Hypotension, Renal Dysfunction, Hyperkalemia No difference in significant renal failure or ESRD 3
4 ACCORD Trial Cardiac outcomes no better; fewer strokes offset by more complications, side effects Ultimately questioned BP Goals for diabetics and methodology for guidelines Less than or equal to 130 mmhg at the time JNC-8 Released December, 2013 Generally Higher (Less Intense) BP Goals Broadened initial BP med recommendations to 4 different categories Very strict trial criteria; only a handful of trials were included Expert Opinion was prevalently used Recommendation 1 In the general population 60 years of age, initiate pharmacologic treatment if SBP is 150 mmhg or DBP is 90 mmhg Strong Recommendation (Grade A) 4
5 Recommendation 1 There is insufficient evidence to support a SBP less than 140 mmhg compared to a goal SBP below 150 mmhg Several panel members dissented and wanted a goal < 140 mmhg based upon Expert Opinion Recommendation 2 In the general population < 60 y/o, initiate pharmacologic therapy for DBP 90 mmhg For y/o, Strong Recommendation For y/o, Expert Opinion Recommendation 3 In the general population < 60 y/o, initiate pharmacologic therapy for SBP 140 mmhg Expert Opinion (Grade E) 5
6 Recommendation 4 In the general population 18 y/o with CKD, initiate pharmacologic therapy for SBP 140 mmhg or DBP 90 mmhg Expert Opinion (Grade E) Recommendation 5 In the general population 18 y/o with DM, initiate pharmacologic therapy for SBP 140 mmhg or DBP 90 mmhg Expert Opinion (Grade E) 6
7 SPRINT Trial Systolic Blood Pressure Intervention Trial A Randomized Trial of Intensive vs. Standard Blood-Pressure Control. The SPRINT Research Group. NEJM. 373;22. Nov 26 th, SPRINT Trial, Inclusion Criteria 9361 Enrolled At least 50 years old SBP 130 mmhg and 180 mmhg NOT Diabetic Increased Cardiovascular Risk SPRINT Trial, Inclusion Criteria Increased Cardiovascular Risk (1 or more) Clinical or subclinical cardiovascular disease other than stroke CRI with GFR 20 to 60 ml/min/1.73 m2 10-year risk of CAD 15% or higher on Framingham Risk Score Age 75 years Not Diabetic 7
8 SPRINT Trial, Randomization Goal SBP 120 mmhg OR Goal SBP 140 mmhg SPRINT Trial, Primary Outcome Primary Outcome was a composite of: Acute Myocardial Infarction Other Acute Coronary Syndromes Heart Failure Stroke Death from Cardiovascular Causes Secondary Outcome included Death from any Cause SPRINT Trial, Results After one year, Average Systolic BP: mmhg in Intensive-Treatment group mmhg in Standard-Treatment group 8
9 SPRINT Trial, Results After one year, Average Diastolic BP: 68.7 mmhg in Intensive-Treatment group 76.3 mmhg in Standard-Treatment group SPRINT Trial, Results Trial stopped after mean of 3.26 years of follow-up due to improvement in primary outcome in Intensive-Treatment group SPRINT Trial, Results Event Rates: 2.19% in Standard-Treatment group 1.65% in Intensive-Treatment group HR % CI [ ], P <
10 SPRINT Results SPRINT Trial, Results All-Cause Mortality HR CI [ ], p < Relative Risk for Cardiac Mortality 43% lower in the Intensive-Treatment group 38% lower risk of Heart Failure with Intensive-Treatment SPRINT Trial, Results New renal insufficiency (30% drop in GFR to < 60) in those without pre-existing CKD: 1.31% in Intensive-Treatment group 0.35% in Standard-Treatment group HR
11 SPRINT Trial, Adverse Reactions Adverse Reactions attributed to the treatment intervention were more common in the Intensive-Treatment group Hypotension, Syncope, Electrolyte Abnormalities, Acute Kidney Injury 4.7% vs. 2.5%. HR 1.88, p < SPRINT Trial, Adverse Reactions Adverse Reactions NOT more common in the Intensive-Treatment group included: Injurious Falls Bradycardia SPRINT Conclusion Goal SBP < 120 mmhg vs < 140 mmhg in non-diabetic patients at increased risk of CV events showed significant mortality and morbidity benefit with increase in relatively mild adverse events 11
12 Considerations Non diabetic patients only Different than ACCORD (Diabetics, no benefit) Minimal to no medication guidelines The Lancet, Meta-Analysis 123 studies met criteria; 613,815 subjects Every 10 mmhg reduction in BP Reduced Major Cardiac Events (RR 0.8) Reduced Coronary Events (RR 0.83) Reduced Stroke (RR 0.73) Reduced CHF (0.72) Reduced All-Cause Mortality (RR 0.83) NO change in renal failure The Lancet, Meta-Analysis Benefits seems to span across all baseline systolic blood pressures Benefit was seen across several baseline co-morbidities (including CAD) Exceptions include DM and CKD, where the benefit was less clear 12
13 The Lancet, Meta-Analysis B-Blockers were inferior to other meds for CAD, CVA, CKD prevention Calcium Channel Blockers were worse in CHF but better for CVA prevention Diuretics were superior for preventing CHF The Lancet, Meta-Analysis Blood pressure lowering significantly reduces vascular risk across various baseline blood pressure levels and comorbidities. Our results provide strong support for lowering blood pressure to systolic blood pressures less than 130 mm Hg and providing blood pressure lowering treatment to individuals with a history of cardiovascular disease, coronary heart disease, stroke, diabetes, heart failure, and chronic kidney disease. The Lancet, Meta-Analysis Authors Commentary This study calls for BP lowering to a greater extent than recommended in current guidelines As there was no lower BP threshold where benefit ceased, they recommended individualizing therapy based upon potential benefit, rather than universal BP goals 13
14 The Lancet, Meta-Analysis Authors Commentary, cont. They emphasized the benefit across multiple co-morbidities and in those both with and without vascular disease. Hence, guidelines could be simplified Lastly, they emphasized benefits of certain medications over the others based upon risk factors or known diseases 2017 ACC/AHA/AAPA/ABC/ACPM/AGS /APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 2017 Guidelines 1/10/HYP full.pdf Hypertension. 2017; HYP , November 13,
15 Collaboration of Societies JNC-7 released December 2003 JNC-8 released December 2013 NHLBI develops JNC ACC and AHA have had independent guidelines since Guideline Updates In 2013, NHLBI (JNC) and ACC/AHA Task Force decided to partner with each other and several other societies to develop unified guidelines The present guidelines were formulated as part of the ongoing efforts the AHA/ACC Task Force in collaboration with NHLBI 2107 Guideline Updates Comprehensive guideline review/updates every 6 years but also when new significant data arises The new guidelines are essentially an update of JNC-8 Guidelines SPRINT Trial likely a major reason for the present update 15
16 Hypertension Defined SBP DBP Normal < 120 mmhg and < 80 mmhg Elevated mmhg and < 80 mmhg Hypertension - Stage mmhg or mmhg - Stage mmhg or 90 mmhg Hypertension - Defined Increased risk of cardiac events and stroke starts at fairly low blood pressure Several meta-analyses of observational data show the following: RR of event is for SBP/DBP of /80-84 mmhg compared to < 120/80 mmhg RR of event is for SBP/DBP of /85-89 mmhg compared to < 120/80 mmhg Hypertension - Defined Severe hypertension is still generally considered to be average BP > 160/100 mmhg This was not extensively addressed in the new guidelines 16
17 Medical Therapy SBP 130 mmhg or DBP 90 mmhg Pharmacologic therapy is indicated for secondary prevention in those with CVD Indicated for primary prevention in adults with a 10 year atherosclerotic disease risk of 10% or higher Medical Therapy SBP 140 mmhg or DBP 90 mmhg Indicated for primary prevention in adults with a 10 year atherosclerotic disease risk of less than 10% ASCVD Risk Calculator
18 ASCVD Risk Calculator Product of ACC and AHA Estimates 10 year risk of an atherosclerotic event Intended for those with LDL < 190 and only for those without known disease (primary prevention) ASCVD Risk Calculator Estimated risk of the following: Nonfatal heart attack Death from coronary artery disease Fatal and nonfatal stroke ASCVD Risk Calculator Demographics Age Valid for ages Gender (Male/Female) Ethnicity Caucasian African American Other May under or overestimate for different ethnicities 18
19 ASCVD Risk Calculator Cholesterol Data Total Cholesterol HDL LDL Blood Pressure Systolic BP ASCVD Risk Calculator Personal History Diabetes On Treatment for Hypertension Smoker Yes, No, Former (When Quit) On a statin for high cholesterol On aspirin therapy ASCVD Risk Calculator Will estimate risk reduction with: Smoking Cessation Start or intensify statin therapy Initiate blood pressure control medications Treat with Aspirin 19
20 ASCVD Risk Calculator Provides advice on lifestyle and Medical Therapy changes Diet and Exercise Salt Restriction, Potassium Supplementation Smoking Cessation Cholesterol/Statin Therapy Starting BP Meds ASCVD Risk Calculator Supposedly better than Framingham-based assessment Pooled cohort data More ethnic diversity Includes more outcomes ASCVD Risk Calculator Factors NOT included but may be relevant Family History (1 st Degree Male < 55, Female < 65) Elevated hscrp Lifetime CVD Risk Coronary Calcium Score Ankle-Brachial Index 20
21 Prevalence The new AHA/ACA guidelines defining HTN as 130/80 mmhg raised the prevalence in the US adult population from 32% to 46% In other words, the new definition just gave a disease to 50 million Americans Measurement of Blood Pressure 1) Properly prepare the patient 2) Use Proper Technique 3) Take the Proper Measurement 4) Properly Document Accurate Readings 5) Average the Readings 6) Provide BP Readings to the Patient White Coat Hypertension Increase of SBP of greater than 20 mmhg and diastolic greater than 10 mmhg This often decreases with familiarity with the clinician as well as throughout the office visit It is also less severe with nurses rather than doctors taking the BP reading 21
22 White Coat Hypertension Measurement of Blood Pressure Properly Prepare the Patient Patient relaxed, sitting in a chair for at least 5 minutes Avoid caffeine, smoking, and exercise for 30 minutes prior to assessment Ensure the patient has emptied their bladder Measurement of Blood Pressure Properly Prepare the Patient Neither patient not observer should talk during the rest period nor during assessment Remove all clothing covering the cuff area Patient should not be sitting or lying on an exam table 22
23 Measurement of Blood Pressure Use Proper Technique Use validated BP measurement device and make sure it s calibrated properly Support the patient s arm (resting on a desk) Position middle of cuff at level of right atrium (mid-sternum) Measurement of Blood Pressure Use Proper Technique Use proper cuff size (80% of bladder encircles the arm) Too small of a cuff falsely increases measurement Too big falsely lowers the reading Use either the bell or diaphragm of the stethoscope Measurement of Blood Pressure Take the Proper Measurement At least at first visit, take BP in both arms and use higher reading from then on Wait 1-2 minutes between repeat measurement For auscultatory measurements use radial artery obliteration first, then inflate mmhg above this level Deflate cuff by 2 mmhg per second 23
24 Measurement of Blood Pressure Properly Document Accurate BP Readings Record SBP and DBP Onset of first Korotkoff sound and disappearance of all Korotkoff sounds Note time of administration of last BP medications Measurement of Blood Pressure Average the Readings Average of 2 readings obtained on 2 different occasions Measurement of Blood Pressure Provide BP Readings to the Patient Provide SBP and DBP readings to patient both verbally and in writing 24
25 AAFP? ACC/AHA/AAPA/ABC/ACPM/AGS/-APhA/ASH/ASPC/NMA/PCNA Notably absent is AAFP ACP and AAFP The American College of Physicians and American Academy of Family Physicians disagree with the ACC/AHA Guidelines They released their guidelines 1/17/2017 Ann Intern Med. 2017;166(6): Non-Endorsement AAFP announced in December 2017 that it does NOT endorse the ACC/AHA Guidelines The ACP and AAFP continue to endorse the 2014 JNC-8 Guidelines 25
26 Non-Endorsement Rationale Guidelines not based upon a sufficient systematic review of the evidence Only 4 key questions had a systematic review out of over 100 recommendations Harms of lower BP goals not systematically reviewed Non-Endorsement Rationale The systematic review that was provided suggested a small benefit for lower BP goals in cardiac events but not mortality, MI, or renal events This review has similar conclusions to that performed for the ACP/AAFP Guidelines Therefore, AAFP recommends shared decision-making with some patients about the risks vs benefits of this Non-Endorsement Rationale The recommendation statements included a grade for the strength of evidence, but assessments of the quality of individual studies or systematic reviews were not provided. 26
27 Non-Endorsement Rationale Substantial weight was given to the SPRINT trial while results from other trials were minimized The SPRINT trial was stopped early due to benefit leading to the potential for exaggerated benefits and an under reporting of harms Non-Endorsement Rationale Conflicts of Interest The Chair of the SPRINT trial steering committee was commissioned as chair of the guideline panel Several other members of the panel also have intellectual conflicts of interest Non-Endorsement Rationale The guideline recommends the use of the ASCVD risk assessment tool to determine whether medications should be initiated for BP control (strong recommendation). This recommendation is not based on evidence that using the tool in this way improves outcomes. 27
28 ACP and AAFP Guidelines Ann Intern Med. 2017;166(6): For adults 60 years and older Published March 2017 ACP and AAFP Guidelines Recommendation #1 Initiate medical therapy at SBP 150 mmhg with goal < 150 mmhg to reduce mortality, stroke, and cardiovascular events Discuss risks/benefits and BP goals with patient first ACP and AAFP Guidelines Recommendation #2 Consider pharmacologic therapy with a goal of SBP < 140 mmhg for patients with a history of TIA or CVA to reduce risk of stroke 28
29 ACP and AAFP Guidelines Recommendation #3 Consider pharmacologic therapy with a goal of SBP < 140 mmhg for patients with high cardiovascular risk, based on individualized assessment, to reduce risk of stroke or cardiac events 29
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationBlood Pressure Measurement in SPRINT
Blood Pressure Measurement in SPRINT Karen C. Johnson, MD, MPH, FAHA Vice Chair, SPRINT Steering Committee University of Tennessee Health Science Center, Department of Preventive Medicine For the SPRINT
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationBlood Pressure Acre Surgery Diviash Thakrar
Blood Pressure Acre Surgery Diviash Thakrar Why Are We Doing This? 1. Improve education for patients within the practice 2. Allow us use this for general health promotion Raise money for charity 3. Raise
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More information2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.
Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationScreening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News
Hot Off the Press and into Your Practice: The Last Year in Medical News Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Moyer VA, et al. Ann Internal Med. 2014;160(5):330-338.
More informationGETTING THE NUMBERS RIGHT: ACCURATE MEASUREMENT OF BLOOD PRESSURE
GETTING THE NUMBERS RIGHT: ACCURATE MEASUREMENT OF BLOOD PRESSURE Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Professor Medicine and Cardiovascular Diseases Director, Seinsheimer Cardiovascular Health
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationVital Signs. Vital Signs. Pulse. Temperature. Respiration. Blood Pressure
Vital Signs Jarvis, Chapter 9 Vital Signs Classic Vital Signs TPR/BP Temperature Pulse Respirations Blood Pressure Additional Vital Signs Height Weight BMI (Kg/m2) or (702Xlbs/in2) Supine, orthostatic
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationHypertension and Cholesterol in the Elderly
Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden
More informationModule 3.2. Management of hypertension at primary health care
Module 3.2 Management of hypertension at primary health care What s inside Introduction Learning outcomes Topics covered Competency Teaching and learning activities Background information Introduction
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More information